Person:
Vivas Balcones, Luis David

Profile Picture
First Name
Luis David
Last Name
Vivas Balcones
URI
https://hdl.handle.net/20.500.14352/80857
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Medicina
Department
Medicina
Area
Medicina
Identifiers
UCM identifierScopus Author IDDialnet ID

Filters

2015 - 20182
Reset filters

Settings

Subject: 615.273.53 ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU
    (Revista Española de Cardiología, 2018) Vivas Balcones, Luis David; Gómez Martínez, Ana María; Ferreiro, José Luis
    Dada la variabilidad y heterogeneidad del manejo de los fármacos antitrombóticos pericirugía, desde la Sociedad Española de Cardiología se coordinó y lideró un documento de consenso con otras 20 sociedades para guiar mediante algoritmos sencillos y de fácil utilización el manejo de estos fármacos en la práctica clínica. During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most of the Spanish scientific societies of clinical specialities that may play a role in the patient-health care process during the perioperative or periprocedural period, is to recommend some simple and practical guidelines with a view to homogenizing daily clinical practice.
  • Thumbnail Image
    Item
    Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Prasugrel-Inhibited Platelets: Results of a Prospective, Randomized, Crossover Study (the ECCLIPSE Trial)
    (Circulation: Cardiovascular Interventions, 2015) Vivas Balcones, Luis David; Martín, Agustín; Bernardo, Esther; Ortega Pozzi, María Aranzazu; Tirado, Gabriela; Fernández, Cristina; Vilacosta, Isidre; Núñez-Gil, Iván; Macaya Miguel, Carlos; Fernández Ortiz, Antonio Ignacio
    Ensayo clínico unicéntrico abierto y cruzado donde se evaluó el efecto en voluntarios sanos sobre la función plaquetaria en función de la administración intravenosa de acetilsalicilato de lisina o aspirina oral. Los sujetos que recibieron acetilsalicilato de lisina intravenosa en comparación con aspirina oral presentaron una inhibición de la función plaquetaria más rápida, potente y con menor variabilidad que aquellos que recibieron aspirina oral. Background— Prasugrel and ticagrelor, new P2Y12-adenosine diphosphate receptor antagonists, are associated with greater pharmacodynamic inhibition and reduction of cardiovascular events compared with clopidogrel in patients with an acute coronary syndrome. However, evidence is lacking about the effects of achieving faster and stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA) compared with oral aspirin on prasugrel-inhibited platelets. Methods and Results— This was a prospective, randomized, single-center, open, 2-period crossover platelet function study conducted in 30 healthy volunteers. Subjects were randomly assigned to receive a loading dose of intravenous LA 450 mg plus oral prasugrel 60 mg or loading dose of aspirin 300 mg plus prasugrel 60 mg orally in a crossover fashion after a 2-week washout period between treatments. Platelet function was evaluated at baseline, 30 minutes, 1 h, 4 h, and 24 h using light transmission aggregometry and vasodilator-stimulated phosphoprotein phosphorylation. The primary end point of the study, inhibition of platelet aggregation after arachidonic acid 1.5 mmol/L at 30 minutes, was significantly higher in subjects treated with LA compared with aspirin: 85.3% versus 44.3%, respectively, P=0.003. This differential effect was observed at 1 hour (P=0.002) and 4 hours (P=0.048), but not at 24 hours. Subjects treated with LA presented less variability and faster and greater inhibition of platelet aggregation with arachidonic acid compared with aspirin. Conclusions— The administration of intravenous LA resulted in a significant reduction of platelet reactivity compared with oral aspirin on prasugrel-inhibited platelets. Loading dose of LA achieves an earlier platelet inhibition and with less variability tan aspirin.